• 1
    Carter HB,Partin AW. Diagnosis and staging of prostate cancer. In: WalshPC,RetikAB,VaughanED,WeinAJ, eds. Campbell's urology,8th edn. Philadelphia: Saunders, 2002. 3209226.
  • 2
    Gretzer MB,Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003; 30: 67786.
  • 3
    Canto EI,Shariat SF,Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003; 30: 26377.
  • 4
    Thompson IM,Pauler DK,Goodman PJ,Tangen CM,Lucia MS,Parnes HL,Minasian LM,Ford LG,Lippman SM,Crawford ED,Crowley JJ,Clotman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 223946.
  • 5
    Adam B-L,Qu Y,Davis JW,Ward MD,Clements MA,Cazares LH,Semmes OJ,Schellhammer PF,Yasui Y,Feng Z,Wright GL,Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostatic hyperplasia. Cancer Res 2002; 62: 360914.
  • 6
    Lehman ES,Cannon GW,Trock BJ,Sokoll LJ,Chan DW,Mangold L,Partin AW,Getzenberg RH. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69: 71420.
  • 7
    Saito S,Levery SB,Salyan MEK,Goldberg RI,Hakomori S. Common tetrasaccharide epitope NeuAcalpha2–3Galbeta1–3(NeuAcalpha2–6)GalNAc, presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities. J Biol Chem 1994; 269: 564452.
  • 8
    Ito A,Levery SB,Saito S,Satoh M,Hakomori S. A novel ganglioside isolated from renal cell carcinoma. J Biol Chem 2001; 276: 16695703.
  • 9
    Saito S,Egawa S,Endoh M,Ueno S,Ito A,Numahata K,Satoh M,Kuwao S,Baba S,Hakomori S,Arai Y. RM2 antigen (β1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer. Int J Cancer 2005; 115: 10513.
  • 10
    FlemmingID,CooperJS,HensonDE,HutterRVP,KennedyBJ, eds. American Joint Committee on Cancer Staging Manual,5th edn. Philadelphia: Lippincott; 1997: 219.
  • 11
    EbleJN,SauterG,EpsteinJI,SesterhennIA, eds. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon (France): IARC Press, 2004: 179.
  • 12
    Saito S,Orikasa S,Ohyama C,Satoh M,Fukushi Y. Changes in glycolipids in human renal-cell carcinoma and their clinical significance. Int J Cancer 1991; 49: 32934.
  • 13
    Mineki R,Taka H,Fujimura T,Kikkawa M,Shindo N,Murayama K. In situ alkylation with acrylamide for identification of cysteinyl residues in proteins during one- and two-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Proteomics 2002; 2: 167281.
  • 14
    Aoki H,Satoh M,Mitsuzuka K,Ito A,Saito S,Funato T,Endoh M,Takahashi T,Arai Y. Inhibition of motility and invasiveness of renal cell carcinoma induced by short interference RNA transfection of β 1,4 GalNAc transferase. FEBS Lett 2004; 567: 2038.
  • 15
    Saito S,Aoki H,Ito A,Ueno S,Wada T,Mitsuzuka K,Satoh M,Arai Y,Miyagi T. Human α 2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase. J Biol Chem 2003; 278: 2647479.
  • 16
    Fujimura T,Shinohara Y,Tissot B,Pang P-C,Kurogochi M,Saito S,Aarai Y,Sadilek M,Murayama K,Dell A,Nishimura S,Hakomori S. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 2008; 122: 3949.
  • 17
    Langlois MR,Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 15891600.
  • 18
    Kurosky A,Barnett DR,Lee TH,Touchstone B,Hay RE,Arnott MS,Bowman BH,Fitch WM. Covalent structure of human haptoglobin: a serine protease homolog. Proc Natl Acad Sci USA 1980; 77: 338892.
  • 19
    Zhang H,Li XJ,Martin DB,Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003; 21: 66066.
  • 20
    Liu T,Qian WJ,Gritsenko MA,Camp DG,II,Monroe ME,Moore RJ,Smith RD. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 2005; 4: 207080.
  • 21
    Tolson J,Bogumil R,Brunst E,Beck H,Elsner R,Humeny A,Kratzin H,Deeg M,Kuczyk M,Mueller GA,Mueller CA,Flad T. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alfa in renal cancer patients. Lab Invest 2004; 84: 84556.
  • 22
    Oh S-K,Kim S-H,Walker JE. Interference with immune response at the level of generating effector cells by tumor-associated haptoglobin. J Natl Cancer Inst 1990; 82: 93440.
  • 23
    McNeal JE,Redwine EA,Freiha ES,Stamey TA. Zonal distribution of prostate adenocarcinoma. Correlation with histologic pattern and distribution of spread. Am J Surg Pathol 1988; 12: 897906.
  • 24
    Wang Y,Kinzie E,Berger FG,Lim S-K,Baumann H. Haptoglobin, an inflammation-inducible plasma protein. Redox Rep 2001; 6: 37985.
  • 25
    Okuyama N,Ide Y,Nakano M,Nakagawa K,Yamanaka K,Moriwaki K,Murata K,Ohigashi H,Yokoyama S,Eguchi H,Ishikawa O,Ito T, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006; 118: 28038.
  • 26
    Oliviero S,Cortese R. The human haptoglobin gene promoter: interleukin-6-responsive elements interact with a DNA-binding protein induced by interleukin-6. EMBO J 1989; 8: 114551.
  • 27
    Ye B,Cramer DW,Skates SJ,Gygi SP,Pratomo V,Fu L,Horick NK,Licklider LJ,Schorge JO,Berkowitz RS,Mok SC. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 290411.
  • 28
    Ahmed N,Oliva KT,Barker G,Hoffmann P,Reeve S,Smith IA,Quinn MA,Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005; 5: 462536.
  • 29
    Gonçalves A,Esterni B,Bertucci F,Sauvan R,Chabannon C,Cubizolles M,Bardou VJ,Houvenaegel G,Jacquemier J,Granjeaud S,Meng X-Y,Fung ET, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006; 25: 9819.
  • 30
    Kwak J-Y,Ma T-Z,Yoo M-J,Choi BH,Kim H-G,Kim S-R,Yim C-Y,Kwak Y-G. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 2004; 32: 83642.
  • 31
    Ang IL,Poon TCW,Lai PBS,Chan ATC,Ngai S-M,Hul AY,Johnson PJ,Sung JJ. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 2006; 5: 2691700.
  • 32
    Bharti A,Ma PC,Maulik G,Singh R,Khan E,Skarin AT,Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 2004; 24: 10318.